Currently Viewing:
Newsroom
Currently Reading
Unmet Care Targets Suggest Need for Improved Diabetes Care Accessibility
August 18, 2019 – Alison Rodriguez
Blood Clots in MPN Related to Higher Cost, Length of Stay for Patients With MPN
August 17, 2019 – AJMC Staff
Researchers Seek to Determine Genetic Variability in Parkinson Progression
August 17, 2019 – AJMC Staff
FDA Panel Backs Use of Descovy for HIV Prevention in Men, Transgender Women
August 16, 2019 – Jaime Rosenberg
Researcher Excited About Future of Psoriasis Treatment
August 16, 2019 – Allison Inserro
This Week in Managed Care: August 16, 2019
August 16, 2019
AJMC® in the Press, August 16, 2019
August 16, 2019 – AJMC Staff
Pediatric Leukemia Treatment Linked to Increased Risk of Infections, Study Finds
August 16, 2019 – Alison Rodriguez
5 Findings From the August 2019 Issue of AJMC®
August 16, 2019 – Christina Mattina

New Device, With Localized Drug Delivery to Pancreatic Tumors, Could Reduce AE

Surabhi Dangi-Garimella, PhD
Mice administered FOLFIRINOX through the implantable device had greater tumor regression and lower tissue toxicity.
Pancreatic cancer is a disease with dismal survival rates (less than 5%) and the second only to non-small cell lung cancer for cancer-related deaths in the United States. A major challenge with treating this disease has been the stromal milieu that surrounds the solid tumor and forms a rigid, impenetrable barrier for chemotherapy. Now, scientists at the University of North Carolina at Chapel Hill have developed a technology that, at least in animal models, has found an Achilles Heel in these tumors.

The researchers have invented an implantable device that can deliver the highly toxic and promising drug cocktail of folinic acid (leucovorin), fluorouracil, irinotecan, and oxaliplatin (together called FOLFIRINOX), directly to the tumor.

“We use the device to hit the primary tumor hard. It’s an exciting approach because there is so little systemic toxicity that it leaves room to administer additional drugs against cancer cells that may have spread in the rest of the body,” according to senior author Jen Jen Yeh, MD, senior author on the study.

According to the paper, published in the Proceedings of the National Academy of Sciences, the iontophoretic device was surgically implanted onto orthotopic patient-derived pancreatic tumors in mice, and the animals were administered saline or FOLFIRINOX through the device, or saline or FOLFIRINOX intravenously (IV). Tumor volumes were measured following treatment completion.

The authors found that 50% of mice who received FOLFIRINOX through the device had significant tumor regression and 1 mouse had stable disease. The mean log2-fold change in tumor volume were 0.4 in mice that received device FOLFIRINOX, 1.9 for IV FOLFIRINOX, 3 for IV saline, and 2.6 for device saline. Additionally, when the tumor tissues were stained for a cell proliferation marker, Ki-67, mice who received FOLFIRINOX through the device had significantly lower expression of the marker, indicating regression of tumor growth. Another important finding of the study was the reduced levels of tissue toxicity with the implanted device, which indicates that these toxic drugs may be better tolerated by patients, and might even improve their quality of life.

“The beauty of this device is that all of the drug delivery is focused locally, with low delivery to the rest of the body,” said James D. Byrne, PhD, the paper’s first author. “If this works in humans, we hope the device can be used as a plug-and-play approach to delivering the latest, most promising drug regimens for patients who have a dire need for new and better treatments.”

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up